Expertise in
6
conditions

Dr. Paul Cook

Infectious Disease
Ecu Health Adult Specialty Care-Infectious Disease Clinic
2390 Hemby Ln, 
Greenville, NC 
Offers Telehealth
44 Years of Experience
Expertise in
6
conditions
Ecu Health Adult Specialty Care-Infectious Disease Clinic
2390 Hemby Ln, 
Greenville, NC 

Overview

Paul Cook is an Infectious Disease provider practicing medicine in Greenville, North Carolina. He has been practicing medicine for over 44 years.

Dr. Cook is highly rated in 6 conditions, according to our data. His clinical expertise encompasses HIV/AIDS, Myelitis, AIDS Dysmorphic Syndrome, and AIDS Dementia Complex.

He is actively involved in clinical research, co-authoring 42 peer reviewed articles and participating in 8 clinical trials.

Graduate Year

1982

Specialties

Infectious Disease

Licenses

Internal Medicine in NC

Hospital Affiliations

Ecu Health Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MetroPlus Health
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Trillium
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Ecu Health Adult Specialty Care-Infectious Disease Clinic
2390 Hemby Ln, Greenville, NC 27834
Other Locations
ECU Health Beaufort Hospital, a Campus of ECU Health Medical Center
628 E 12th St, Washington, NC 27889

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: June 04, 2024
Intervention Type: Drug
Study Drugs: Cabotegravir, Rilpivirine, BIKTARVY
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab
Study Phase: Phase 2/Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients With COVID-19 Infection
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients With COVID-19 Infection
Enrollment Status: Completed
Publish Date: July 28, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
Enrollment Status: Completed
Publish Date: July 01, 2022
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab, LY3853113 Anti-COVID-19 Antibody, VIR-7831 Anti-COVID-19 Antibody
Study Phase: Phase 2
A Randomized, Placebo-Controlled, Double-Blind, Sponsor Unblinded, Single Ascending Dose, Phase 1 First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous LY3819253 in Participants Hospitalized for COVID-19
A Randomized, Placebo-Controlled, Double-Blind, Sponsor Unblinded, Single Ascending Dose, Phase 1 First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous LY3819253 in Participants Hospitalized for COVID-19
Enrollment Status: Completed
Publish Date: November 12, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Double-blind, Placebo-controlled, Clinical Trial of LY3127804 in Patients Who Are Hospitalized With Pneumonia and Presumed or Confirmed COVID-19
A Randomized, Double-blind, Placebo-controlled, Clinical Trial of LY3127804 in Patients Who Are Hospitalized With Pneumonia and Presumed or Confirmed COVID-19
Enrollment Status: Terminated
Publish Date: August 12, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3, Multicenter, Expanded Access Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant (MDR) HIV-1
A Phase 3, Multicenter, Expanded Access Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant (MDR) HIV-1
Enrollment Status: Completed
Publish Date: March 11, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
Enrollment Status: Completed
Publish Date: January 05, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

42 Total Publications

Deciphering the miR-29c-3p / TET3 regulatory axis within the SARS-CoV-2-infected midbrain.
Deciphering the miR-29c-3p / TET3 regulatory axis within the SARS-CoV-2-infected midbrain.
Journal: Virology
Published: February 25, 2026
Similar Doctors
Expertise in
8
conditions
Dr. Thomas Gallaher
Infectious Disease
Expertise in
8
conditions
Dr. Thomas Gallaher
Infectious Disease
Referral may be required

Ecu Health Adult Specialty Care-Infectious Disease Clinic

2390 Hemby Ln, 
Greenville, NC 
 (0.5 miles away)
252-744-4500
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Thomas Gallaher is an Infectious Disease provider practicing medicine in Greenville, North Carolina. Dr. Gallaher is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Osteomyelitis, Osteomyelitis in Children, Cellulitis, and Nontuberculous Mycobacterial Lung Disease.

Expertise in
8
conditions
Dr. Octavio Cieza
Infectious Disease
Expertise in
8
conditions
Dr. Octavio Cieza
Infectious Disease
Referral may be required

Office

507 N Brightleaf Blvd Ste 201, 
Smithfield, NC 
 (52.9 miles away)
919-938-7716
Languages Spoken:
English
See accepted insurances

Octavio Cieza is an Infectious Disease provider practicing medicine in Smithfield, North Carolina. Dr. Cieza is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Osteomyelitis, Osteomyelitis in Children, Lymphangitis, and Cellulitis.

Expertise in
4
conditions
Dr. Alexandra Stang
Infectious Disease
Expertise in
4
conditions
Dr. Alexandra Stang
Infectious Disease
Referral may be required

Ecu Health Adult Specialty Care-Infectious Disease Clinic

2390 Hemby Ln, 
Greenville, NC 
 (0.5 miles away)
252-744-4500
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Alexandra Stang is an Infectious Disease provider practicing medicine in Greenville, North Carolina. Dr. Stang is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses HIV/AIDS, Myelitis, AIDS Dysmorphic Syndrome, and AIDS Dementia Complex.

Frequently Asked Questions about Dr. Paul Cook

How do I make an appointment with Dr. Paul Cook?

You can book an appointment with Dr. Paul Cook by calling their office at 252-744-4500. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Paul Cook a top-rated expert for HIV/AIDS?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Paul Cook is classified as an Advanced expert for HIV/AIDS, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Paul Cook specialize in?

While Dr. Paul Cook is a Infectious Disease, they have specific expertise in HIV/AIDS, Myelitis, and AIDS Dysmorphic Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Infectious Disease.

Does Dr. Paul Cook participate in research or clinical trials?

Yes. Dr. Paul Cook has published 42 articles and abstracts on conditions like HIV/AIDS. You can view a list of Dr. Paul Cook's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Paul Cook accept my insurance?

Dr. Paul Cook accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 252-744-4500 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cook's expertise for a condition
ConditionClose
      View All 10 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile